We’re pleased to announce that Entyvio® (vedolizumab)—available in both IV and subcutaneous pen formats—is now part of the Prodigy Health portfolio.
Entyvio is a gut-selective biologic approved for moderate-to-severe ulcerative colitis and Crohn’s disease, offering flexible options to support varied care settings and patient needs.
With a decade of real-world experience and regulatory approval, Entyvio represents an important treatment option for those managing inflammatory bowel disease (IBD). The availability of both clinic-based and at-home administration formats allows providers and patients to tailor care around convenience and access.
At Prodigy Health, we’re proud to support specialty providers with responsive service, reliable cold chain distribution, and a deep commitment to patient well-being.
📞 To learn more or place an order, contact us at 877-693-4376 or orders@prodigyhealth.com
